

Organoids Market Competition Analysis 2026: How Players Are Shaping Growth

The Business Research Company's Organoids Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035

LONDON, GREATER LONDON, UNITED KINGDOM, January 8, 2026

/EINPresswire.com/ -- [The Organoids market](#) is dominated by a mix of global established biotechnology companies,

specialized life-science tool providers, and emerging academic spin-offs. Companies are focusing on advanced 3D cell culture technologies, stem-cell-derived organoid platforms, and improved scalability and reproducibility to strengthen market presence and support drug discovery and disease modeling. Understanding the competitive landscape is critical for stakeholders seeking growth opportunities, research collaborations, and strategic partnerships across pharmaceuticals, biotechnology, and academic research institutions.

Companies are focusing on advanced 3D cell culture technologies, stem-cell-derived organoid platforms, and improved scalability and reproducibility to strengthen market presence and support drug discovery and disease modeling. Understanding the competitive landscape is critical for stakeholders seeking growth opportunities, research collaborations, and strategic partnerships across pharmaceuticals, biotechnology, and academic research institutions.

improved scalability and reproducibility to strengthen market presence and support drug discovery and disease modeling. Understanding the competitive landscape is critical for stakeholders seeking growth opportunities, research collaborations, and strategic partnerships across pharmaceuticals, biotechnology, and academic research institutions.

Which Market Player Is Leading the Organoids Market?

According to our research, Thermo Fisher Scientific Inc. led global sales in 2024 with a 7% market share. The Life Sciences Solutions division of the company is partially involved in the organoids market, provides the instruments, reagents and consumables for biological and medical research, diagnosis of disease and discovery and production of new medicines and vaccines.

[How Concentrated Is the Organoids Market?](#)

The market is concentrated, with the top 10 players accounting for 34% of total market revenue in 2024. This level of concentration reflects the high entry barriers driven by complex scientific requirements, regulatory-aligned bioprocessing standards, and the demand for validated, scalable 3D biological systems. Leading companies such as Thermo Fisher Scientific Inc., Corning Incorporated, Merck KGaA's Hubrecht Organoid Technology, STEMCELL Technologies, Danaher Corporation's Cellectis Ltd, and Sartorius AG shape the competitive landscape through advanced culture media, extracellular matrices, bioprocessing tools, and automated organoid



The Business Research Company's Organoids Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035

expansion platforms. Their established expertise, intellectual property strength, and long-standing partnerships with biotechnology and pharmaceutical organizations position them at the forefront of innovation, while smaller firms primarily support niche research needs. As organoid adoption accelerates across drug discovery, disease modelling, and personalized medicine, the market is expected to experience deeper collaboration, technology integration, and strategic alliances—further reinforcing the dominance of major players.

- Leading companies include:
 - o Thermo Fisher Scientific Inc. (7%)
 - o Corning Incorporated (5%)
 - o Merck KGaA (Hubrecht Organoid Technology (HUB)) (5%)
 - o STEMCELL Technologies (4%)
 - o Danaher Corporation (Cellesce Ltd) (3%)
 - o Sartorius AG (3%)
 - o Charles River Laboratories International, Inc. (3%)
 - o Bio-Techne Corp. (3%)
 - o Greiner Bio-One International GmbH (2%)
 - o ACRO Biosystems Inc. (1%)

Request a free sample of the Organoids Market report:

https://www.thebusinessresearchcompany.com/sample_request?id=10787&type=smp

Which Companies Are Leading Across Different Regions?

- North America: STEMCELL Technologies Inc., 3Dnatics Inc., Organoid Therapeutics, PeproTech Inc., Thermo Fisher Scientific Inc., Corning Incorporated, Bio-Techne Corporation, Path BioAnalytics Inc., PATH Biotech, R&D Systems Inc., Merck KGaA, Advanced BioMatrix Inc., Synthego Corporation, Visikol Inc., Organovo Holdings Inc., American Type Culture Collection (ATCC), Lonza Group AG, Prellis Biologics Inc., Eli Lilly and Company, Cell Microsystems Inc., Molecular Devices LLC, ViaCyte Inc., ChristianaCare and ACROBiosystems Inc. are leading companies in this region.
- Asia Pacific: Inventia Life Science Pty Ltd, Shanghai Biochip Co. Ltd., RIKEN, Samsung Biologics Co., Ltd., CHA Biotech Co., Ltd., Organoid Therapeutics, Nanoscribe GmbH & Co. KG, Crown Bioscience Inc., Cellapy Biotechnology, Cellenion SAS, RIKEN Institute, STEMCELL Technologies Inc. and BioSpherix Ltd are leading companies in this region.
- Western Europe: HCS Pharma, TreeFrog Therapeutics, Cellendes GmbH, Hubrecht Organoid Technology, InSCREENeX GmbH, Ocello B.V., Netherlands Translational Research Center, STEMCELL Technologies Inc., Astarte Biologics, AMSBIO, DefiniGEN Ltd., Kirkstall Ltd. and Molecular Devices LLC are leading companies in this region.
- Eastern Europe: 3D Bioprinting Solutions, STEMCELL Technologies Inc., Mimetas B.V., Cellesce Ltd., Crown Bioscience Inc., Lonza Group AG, InSphero AG, Hubrecht Organoid Technology and Selvita S.A. are leading companies in this region.
- South America: Tecan Group Ltd., Inventia Life Science, InSphero AG, Lonza Group AG, Thermo Fisher Scientific Inc., Merck KGaA, GCell 3D and Organovo Holdings, Inc. are leading companies in

this region.

What Are the Major Competitive Trends in the Market?

- Focus on vascularized and functionally mature organoid models is transforming disease modelling, regenerative therapies, and drug testing applications.
- Example: Cincinnati Children's Hospital Medical Centre Liver Organoid (June 2025) assigns critical coagulation factors, including Factor VIII, and were able to correct bleeding in haemophilia-model mice.
- These innovations helps overcome the long-standing limitation of organoids lacking internal vasculature, and may pave the way for transplantable liver tissue, enhanced disease models, and novel therapies for coagulation disorders.

Which Strategies Are Companies Adopting to Stay Ahead?

- Launching innovative organoid and 3D cell-culture solutions to strengthen market position
- Enhancing investment in advanced 3D tissue engineering and bioprocessing capabilities
- Focusing on stem cell innovation and next-generation organoid development platforms
- Leveraging automation, AI-driven analytics, and high-throughput culture systems for scalable organoid production

Access the detailed Organoids Market report here:

<https://www.thebusinessresearchcompany.com/report/organoids-global-market-report>

[The Business Research Company \(www.thebusinessresearchcompany.com\)](https://www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. We have published over 17,500 reports across 27 industries and 60+ geographies. Our research is powered by 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

We provide continuous and custom research services, offering a range of specialized packages tailored to your needs, including Market Entry Research Package, Competitor Tracking Package, Supplier & Distributor Package and much more.

Disclaimer: Please note that the findings, conclusions and recommendations that TBRC Business Research Pvt Ltd delivers are based on information gathered in good faith from both primary and secondary sources, whose accuracy we are not always in a position to guarantee. As such TBRC Business Research Pvt Ltd can accept no liability whatever for actions taken based on any information that may subsequently prove to be incorrect. Analysis and findings included in TBRC reports and presentations are our estimates, opinions and are not intended as statements of fact or investment guidance.

The Business Research Company

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email: info@tbrc.info"

Oliver Guirdham

The Business Research Company

+44 7882 955267

info@tbrc.info

This press release can be viewed online at: <https://www.einpresswire.com/article/881121256>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2026 Newsmatics Inc. All Right Reserved.